Quantcast

Latest Protease inhibitor Stories

2011-07-06 06:00:00

HUDDINGE, Sweden, July 6, 2011 /PRNewswire/ -- Medivir AB (OMX: MVIR), is an emerging research-based specialty pharmaceutical company focused on infectious diseases. Medivir today announced that its investigational protease inhibitor TMC435 has received "Fast Track" designation by the U.S. Food and Drug Administration ("FDA") for the treatment of chronic hepatitis C (CHC) genotype-1 infection. This is based on TMC435's potential to address unmet medical needs in the...

2011-07-06 05:45:00

PRINCETON, N.J., July 6, 2011 /PRNewswire/ -- Pharmasset, Inc. (NASDAQ: VRUS), announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate in a Phase 2 study the safety and efficacy of PSI-7977, Pharmasset's investigational nucleotide polymerase inhibitor, in combination with TMC435, Tibotec Pharmaceuticals' investigational protease inhibitor, for the treatment of chronic hepatitis C virus (HCV). This phase 2 proof of concept study...

2011-06-21 00:00:28

HepatitisRxAssist program from BioPlus Specialty Pharmacy helps patients secure needed medications, manage side effects, and adhere to their treatment plan for the best possible outcomes with the new protease inhibitor medications. Altamonte Springs, FL (PRWEB) June 20, 2011 BioPlus Specialty Pharmacy (BioPlus), one of the nation's leading specialty pharmacies, is announcing today enhancements to their hepatitis C patient support program called HepatitisRxAssist. The FDA's recent approval...

2011-06-03 12:39:40

Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy. Reported in the journal Clinical Cancer Research, the study determined the maximum tolerated dose with acceptable side effects for this novel drug combination. The trial...

2011-04-29 14:02:11

Use of chemical systems biology may represent the future of drug discovery Researchers at the University of California, San Diego and Hunter College of the City University of New York (CUNY) have identified potential human molecular targets of the anti-HIV drug Nelfinavir, which may explain why the drug is also effective as a cancer therapy. Their study will be published in the online edition of PLoS Computational Biology on April 28. Nelfinivir is a protease inhibitor that prevents...

2011-04-29 13:34:53

Potential molecular targets of the anti-HIV drug nelfinavir have been identified, and may explain why the drug is also effective as a cancer therapy. Findings will be published in the open-access journal PLoS Computational Biology on 28th April 2011. Nelfinavir is a protease inhibitor that prevents replication of the HIV virus. It has also been found to have a positive effect on a number of solid tumor types but the mechanism of how the drug worked in humans was unclear. Researchers from the...

2011-04-26 08:00:00

RIDGEFIELD, Conn., April 26, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that enrollment has commenced at North American sites in its pivotal Phase 3 clinical trial program for BI 201335, the Company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV). Phase 3 trials have begun recruiting to evaluate BI 201335 plus standard-of-care (SOC) in both treatment-naive and -experienced patients with chronic genotype-1...

2011-04-03 21:53:40

Rapid resistance to novel anti-viral therapy develops in response to direct antiviral drugs Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus (HCV) must be prescribed and monitored by experts and specialists to ensure resistance is minimized. Several studies observed the rapid onset of HCV resistance in patients treated with NS3-protease, NS5b-polymerase and NS5a inhibitors. Although these direct...

2011-04-02 01:00:00

RIDGEFIELD, Conn., April 2, 2011 /PRNewswire/ -- Boehringer Ingelheim today announced a preview of the study designs for the pivotal Phase 3 clinical trials evaluating BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus (HCV), the most challenging genotype to treat. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development programs for BI...

2011-04-01 09:00:00

BERLIN and RIDGEFIELD, Conn., April 1, 2011 /PRNewswire/ -- New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 (GT1) hepatitis C virus (HCV), the most challenging genotype of HCV to treat. Results from SILEN-C1 show a sustained viral response (SVR)...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'